A decade after Bristol Myers Squibb first won approval for its PD-1 checkpoint inhibitor Opdivo, the cancer drug has been ...

BioNTech settles with NIH and UPenn over Comirnaty royalties, paying $750M to NIH and $400M to UPenn for 2020-2023, with ...

WuXi Apptec will sell its Advanced Technologies unit to the US private equity firm Altaris for an undisclosed amount, a ...

J&J partners with Kaken on STAT6 program, getting rights to KP-723 oral inhibitor. Kaken receives $30M upfront, potential $1.2B in milestone payments after Phase 1.

Bristol Myers Squibb's Sotyktu succeeds in Phase 3 psoriatic arthritis trials, as company leads TYK2 race against Takeda & ...

The Centers for Medicare and Medicaid Services on Friday released detailed but heavily redacted explanations of how it ...

The FDA on Friday issued two simultaneous cystic fibrosis approvals for Vertex Pharmaceuticals, but included boxed safety ...

Sumitomo Pharma’s oral treatment for overactive bladder symptoms has won an expanded label from the FDA, and is now approved ...

Applied Therapeutics CEO Shendelman exits; CFO Funtleyder becomes interim CEO after FDA rejects govorestat. Company withdraws ...

Generic drug firm Viatris announced Monday that one of its India-based manufacturing facilities has been placed on import ...

Novo Nordisk's CagriSema fell short of weight loss goals, causing 17% stock drop. Drug shows similar results to Eli Lilly's ...

House Speaker Johnson and GOP push for narrow spending bill without healthcare reforms as midnight shutdown deadline looms; ...